Pharmaceutical Technology

JUNE 30, 2022

In the same space, a different team of Cambridge scientists used whole genome sequencing to map out the largest sample of mutational signatures yet. The team identified 58 entirely new signatures and developed a computer tool that can help oncologists spot these signatures in individual patients.

Genome Project 130

Genome Project Genome Genomics DNA 130

Drug Discovery World

AUGUST 16, 2023

Over the next two decades, it is quite possible that most new drugs approved could be based on some form of RNA, whether it be through its delivery or targeting the molecule itself. In actuality, the protein-coding portion of our genome is comparable in identity and number with the humble fruit fly or worm.

RNA 52

RNA Genome Genomics DNA 52

pharmaphorum

FEBRUARY 26, 2021

With only <10% of the affected people having treatment for their rare condition, the question remains – what impedes the process of developing a treatment for such diseases? The domain is marred with poorly-developed study endpoints and insufficient patient data.

Drugs 78

Drugs Genome Project Genome Genomics 78

Drug Discovery World

SEPTEMBER 20, 2022

Breakthroughs in gene therapy are only possible with an exact understanding of the genetic underpinnings of disease. To develop safe and effective gene therapies, researchers need confidence that genomic data is both complete and accurate. Recent years have seen a great deal of progress in both short- and long-read sequencing.

Gene Therapy 52

Gene Therapy Gene Genome Genomics 52

XTalks

NOVEMBER 3, 2023

After spending almost an entire day deliberating the safety of Vertex Pharmaceuticals’ and CRISPR Therapeutics’ CRISPR-based gene therapy exa-cel for sickle cell disease, a US Food and Drug Administration (FDA) advisory panel appears to be satisfied with what it saw. CRISPR works as genetic scissors to edit parts of the genome.

Gene Therapy 59

Gene Therapy Gene Gene Editing In-Vivo 59

XTalks

APRIL 5, 2021

The Human Genome Project could not have succeeded without the use of bioinformatics. Since the conclusion of the project in 2003, bioinformatics tools have been used to identify genes and elucidate their function with the aim of developing gene-based strategies for disease prevention, diagnosis and treatment.

Bioinformatics 59

Bioinformatics Engineer Scientist Genome 59

Drug Discovery World

MARCH 6, 2024

The development of effective new disease-modifying treatments in neurodegenerative and neuropsychiatric disorders has been hindered by their inherent genetic complexity, environmental influences, and clinical variability. This has been the real failure of some areas of CNS drug discovery. This is wholly unsurprising.

Genome 64

Genome Genomics Clinical Trials Clinical Trials 64

pharmaphorum

SEPTEMBER 13, 2022

Similar to Newbury, McBean – known to be a highly respected tradesman – developed fatigue and severe pain from weak and easily broken bones. During this period, Nobel prize-winning German scientist Paul Ehrlich developed his lock-key hypothesis of molecules that specifically bind to cell receptors.

Genome Project 98

Genome Project Genome Genomics DNA 98

Drug Discovery World

JULY 19, 2023

The tide has been turning in the worlds of diagnostics and drug development. Bioinformatics and genetic sequencing are starting to be placed front and centre of public research programmes as scientists from around the world recognise the substantial benefits of knowledge sharing and resource pooling when it comes to genetic science.

Genome 52

Genome Genomics Bioinformatics Genetics 52

pharmaphorum

SEPTEMBER 14, 2020

Last week geneticist Dr Charles Steward shared with us his experiences of searching for a genetic cause for his children’s rare neurological diseases. Here he gives us a deeper look at how genomic medicine is evolving and the barriers that are preventing it from reaching its full potential.

Genome 119

Genome Genomics Medicine Gene 119

pharmaphorum

APRIL 20, 2022

The potential of CRISPR technology has been a hot topic in the industry ever since it was first developed, but as trials progress further into the clinic, what therapeutic areas could be set to benefit? Cancer is a genetic disease, caused by certain changes in the way that genes control cell function, such as how they grow and divide.

Gene Editing 52

Gene Editing DNA Gene Genetics 52

Drug Discovery World

OCTOBER 6, 2022

In pursuit of this, the number of new therapeutics in development has boomed. In the cancer space alone over the last five years, clinical trials have increased 500% for new drugs and new drug combinations. New classes of therapies have added to this growth, including immune checkpoint inhibitors and genome targeted therapies.

Medicine 52

Medicine Clinical Trials Clinical Trials Genome 52